Research and development of drugs and diagnostic reagents, as well as research and development of new energy sources. On the basis of research, genetic engineering, vector construction and genetic information analysis are carried out. In February 2000, Macrogen became the first GEM in Korea.
(Kosdaq) listed biomedical enterprises. In 20 1 1 year, Macrogen successfully ranked among the top 500 global new energy enterprises. At present, Macrogen has been in Asia, Europe and the United States.
A number of branches have been established, and long-term cooperative relations have been maintained with more than 1 10,000 scientific research units in more than 100 countries around the world.
From June, 5438 to February, 2009, Macrogen China subsidiary Millennium Gene Technology Co., Ltd. was formally established in Shenzhen. Our goal is to serve the scientific research workers in China and serve the country with the most competitive technology in the world.
Genome technology supports the industry to create a new situation. Through the strong technical support of Macrogen Group, we insist on the best quality of results, service quality and scientific integrity. So far, we have worked with
From China Academy of Sciences, China University of Science and Technology, China Agricultural University, China Academy of Agricultural Sciences, Shandong Academy of Agricultural Sciences, Guangdong Academy of Agricultural Sciences, Sun Yat-sen University, Shanghai Jiaotong University, Tongji University, Xi Jiaotong University,
Hundreds of researchers from the Third Military Medical University, Southern Medical University, Sichuan Provincial People's Hospital, Huaxi Hospital, Xiangya Hospital, Institute of Science and Technology of National Family Planning Commission, Hong Kong University, Chinese University of Hong Kong, Hong Kong University of Science and Technology, Shantou International Eye Center, Sun Yixian Eye Center of Sun Yat-sen University and other units have established extensive cooperation.